Search results
20 hours ago · Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immuno-oncology fields, is conducting randomized, placebo-controlled Phase 2 clinical trials of ...
6 hours ago · Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general ...
20 hours ago · Questor: Top fund managers are betting this pharma giant turns things around. It takes a long time and a lot of effort to turn a tanker. Shareholders in French pharma giant Sanofi know this all ...
20 hours ago · As Sanofi navigates through its early-year challenges, current metrics from InvestingPro paint an intriguing picture of the company's financial health and market performance. With a robust Market Cap of $125.98 billion and a Price to Earnings (P/E) ratio sitting at 12.83, Sanofi demonstrates a solid footing in the market.
7 hours ago · New Delhi: Noting an unmet medical need, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug major Sanofi Healthcare to import and market Belumosudil tablets 200 mg, with a condition to conduct a Phase IV clinical trial (CT) study involving high-volume transplant centers (more than 100) across the country.
20 hours ago · KT-474 was the first heterobifunctional small molecule protein degrader to enter clinical development for immunological diseases. Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immuno-oncology fields, is conducting randomized, placebo-controlled Phase 2 clinical trials of KT-474 in both HS ...
20 hours ago · (AOF) - Sanofi (+1,92% à 92,69 euros) Le groupe pharmaceutique joue son rôle de valeur refuge dans un contexte d'incertitude politique. Le titre progresse de plus de 3% depuis le début de l'année.
